DrugInformer Search


Ingredients: Pralatrexate
Average User Review Score
* Based on 0 reviews from across the web.

Pralatrexate (brand name Folotyn) is an anti-cancer therapy. It is the first drug approved as a treatment for patients with relapsed or refractory peripheral T-cell lymphoma, or PTCL — a biologically diverse group of aggressive blood cancers that have a poor prognosis.

Read more on Wikipedia

  Please use Workbench for in-depth research on Folotyn.

* Extracted from FDA Adverse Event Reports for all drugs with the same active ingredients.

Tell us about your Experience with Folotyn

Thank you for sharing your experience with us!

Share Your Experience

Druginformer Identified Side Effects: None

Posted By stkitt in healingwell.com on March 24, 2011 @ 12:00 am

Good Morning, Pralatrexate injection is used to treat peripheral T-cell lymphoma (PTCL; a form of cancer that begins in a certain type of cells in the immune system) that has not improved or tha...

Druginformer Identified Side Effects: None

Posted By davecholly in healingwell.com on March 23, 2011 @ 12:00 am

Today my hematologist mentioned a drug that is relatively new on the market [The FDA approved it in September of 2009 under what they call an accelerated approval because it meets unmet medical needs)...

* Warning: The facts and figures contained in these reports are accurate to the best of our capability; however, our metrics are only meant to augment your medical knowledge, and should never be used as the sole basis for selecting a new medication. As with any medical decision, be sure to work with your doctor to ensure the best choices are made for your condition.

* About FAERS: The FDA Adverse Event Reporting System (FAERS) is used by FDA for activities such as looking for new safety concerns that might be related to a marketed product, evaluating a manufacturer's compliance to reporting regulations and responding to outside requests for information. Reporting of adverse events is a voluntary process, and not every report is sent to FDA and entered into FAERS. The FAERS database may contain duplicate reports, the report quality is variable, and many factors may influence reporting (e.g., media attention, length of time a drug is marketed, market share). For these reasons, FAERS case reports cannot be used to calculate incidence or estimates of risk for a particular product or compare risks between products.